Bruno Sangro
MD, PhD
Professor and Director, Liver Unit
👥Biography 个人简介
Bruno Sangro is a hepatologist and HCC oncologist who contributed to the landmark CheckMate 040 trial establishing nivolumab activity in sorafenib-refractory HCC. He has investigated combinations of locoregional therapies with systemic immunotherapy and the HIMALAYA trial of tremelimumab plus durvalumab in advanced HCC. His research integrates translational biomarker studies with clinical outcomes in HCC immunotherapy. He co-chairs the EASL HCC clinical practice guidelines and leads international HCC educational programs.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Bruno Sangro 的研究动态
Follow Bruno Sangro's research updates
留下邮箱，当我们发布与 Bruno Sangro（Clinica Universidad de Navarra）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment